Form 4: Amylyx Co-CEO Sells Shares for Tax Obligations

Amylyx Pharmaceuticals Co-CEO Joshua B. Cohen sold 7,715 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Joshua B. Cohen, Co-Chief Executive Officer and Director of Amylyx Pharmaceuticals, Inc. (AMLX), reported a transaction on January 6, 2026.
• The transaction involved the sale of 7,715 shares of Amylyx common stock.
• The shares were sold at a weighted average price of $11.0948 per share, with individual sales ranging from $11.05 to $11.14.
• The sale was non-discretionary and executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Joshua B. Cohen beneficially owns 3,317,632 shares of Amylyx common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a non-discretionary sale to cover tax obligations, which is a routine event and does not reflect a change in the insider's view of the company's prospects.

Positives

• The sale was non-discretionary, indicating it was not a voluntary divestment based on a change in outlook but rather a pre-arranged tax obligation.

Negatives

• A reduction in direct insider ownership, albeit for tax purposes, slightly decreases the alignment of management's direct equity interest with shareholders.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The shares were required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.
• Such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically a non-discretionary sale to cover tax obligations, which is common practice for executives receiving equity compensation across various industries, including biotechnology.

Stakeholder Impact

• Shareholders: The impact is minimal as the sale is for tax purposes and not a discretionary divestment, suggesting no change in the executive's confidence in the company. The executive retains substantial beneficial ownership.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

The transaction reported is a non-discretionary sale by a Co-CEO to cover tax obligations related to RSU vesting. Such sales are routine and do not typically signal a change in the company's fundamentals or the executive's long-term outlook. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Amylyx Pharmaceuticals, AMLX, Joshua B. Cohen, Insider Trading, Form 4, Stock Sale, Executive Compensation, Restricted Stock Units, Tax Withholding